VIKAS KUNDRA to Radiopharmaceuticals
This is a "connection" page, showing publications VIKAS KUNDRA has written about Radiopharmaceuticals.
Connection Strength
0.752
-
Hybrid magnetic resonance and PET imaging for prostate cancer recurrence. Curr Opin Oncol. 2023 05 01; 35(3):231-238.
Score: 0.150
-
Noninvasive monitoring of somatostatin receptor type 2 chimeric gene transfer. J Nucl Med. 2002 Mar; 43(3):406-12.
Score: 0.140
-
Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? AJR Am J Roentgenol. 2020 06; 214(6):1248-1258.
Score: 0.122
-
In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized 13C-Pyruvate MR Spectroscopy and 18F-FDG PET/CT Imaging in a Mouse Model. Radiology. 2017 12; 285(3):830-838.
Score: 0.102
-
Somatostatin receptor type 2-based reporter expression after plasmid-based in vivo gene delivery to non-small cell lung cancer. Mol Imaging. 2013 Oct; 12(7):1-10.
Score: 0.078
-
Noninvasive assessment of gene transfer and expression by in vivo functional and morphologic imaging in a rabbit tumor model. PLoS One. 2013; 8(6):e62371.
Score: 0.077
-
Signaling can be uncoupled from imaging of the somatostatin receptor type 2. Mol Imaging. 2007 Nov-Dec; 6(6):427-37.
Score: 0.052
-
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53.
Score: 0.018
-
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007 Oct 01; 67(19):9337-45.
Score: 0.013